Arrowhead Cleared By FDA For Phase 2b Hepatitis B Study

The drug known as ARC-520 has been cleared by the FDA to proceed with multi-dose trial in hepatitis B patients but shares only briefly rallied before returning flat.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.